Health & Wellness
Parag Saxena knows a thing or two about making early bets on innovations in health and technology. He has raised billions of dollars of capital in both private and public markets around the world.
Parag has led or been a part of over 80 healthcare venture investments in the areas of pharma-biotech, digital health, medical devices, hospital management and health insurance over three decades. He made early investments companies like Amgen and Celgene as well in nearly 80 healthcare technology companies including Genomic Health, Alkermes, Masimo, Transgenomic, Horizon Health Corp., Xenon Pharmaceuticals. His other signature investments include Starbucks, MetroPCS, Costco, Punjab National Bank Housing Finance, VRL Logistics and Café Coffee Day.
A keen student of health outcomes Parag is excited at the possibilities that exist today and the the collective power of advances in genomics, artificial intelligence, behavioral economics, precision medicine. Parag believes that “This convergence will transform in every aspect of healthcare”.
Parag is a long-time investor with over 35 years in the business having led Invesco Private Capital for nearly 23 years. He then co-founded Vedanta Capital and New Silk Route over a decade ago which he leads as their CEO. Forbes’ Midas List of Top Investors which ranks the top global investors has picked him multiple times for his investments in companies like Amgen, MetroPCS and others. Over the years, Parag has either led or been a part of teams that have invested in companies that have a market value of $USD 500 billion and created hundreds of thousands of jobs across many sectors ranging from healthcare to consumer services to telecommunications, manufacturing and education.
Previously, he was Chief Executive Officer of Invesco Private Capital (and its predecessor firms), a venture capital firm in the U.S. During his 23-year tenure at Invesco, over 300 investments were made, including Amgen, Costco, PictureTel, Polycom, Staples and Starbucks. Mr. Saxena led more than 90 investments for Invesco Private Capital (and its predecessor firms), a third of which went on to become public companies. These investments include Alkermes, Celgene, Genomic Health, Indigo, Masimo, Transgenomic, Xenon Pharmaceuticals, Amber Networks, ARM Holdings, Horizon Health Corp. and MetroPCS. He started his investing career in 1983 with Citicorp Investment Management (later became Chancellor Management).
A graduate of the University of Pennsylvania’s Wharton School of Business where he earned his MBA, he received his Bachelor of Technology degree from the Indian Institute of Technology, Bombay, India, and his M.S. in Chemical Engineering from The University of West Virginia.
An active supporter of the arts and culture, Parag is an Advisor for the India Advisory Board at Brown University and at the University of Pennsylvania’s Center for the Advanced Study of India. He is also a Global Advisory Board Member of the Wilson Center, in Washington D.C. and on the Economic Advisory Council for the Center for American Progress.
Parag is also on the U.S. Advisory Council for the Royal Shakespeare Company and has served on Mayor Michael Bloomberg’s Applied Sciences Advisory in New York.
Parag is a strong supporter of early primary education and takes the time to educate himself and those around him on the latest developments in preventing disease and imbibing healthy habits including creativity in exercise and healthy cuisines.
Watch Out for Parag’s Post on Health & Wellness…